Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data.

Abstract:

BACKGROUND:The aim of this study was to analyse registry data of seizure outcome and adverse events (AEs) for perampanel as add-on therapy in patients with focal epilepsy since its approval in 2012 for adjunctive treatment of focal epilepsy in patients ⩾12 years. METHOD:A retrospective 2-year chart review of all patients receiving perampanel was carried out. RESULTS:A total of 122 patients received perampanel [median treatment length: 20.1 (range: 3.4-26.8) months]; 71 (58%) remained on treatment at last follow up. Overall, 33 patients (27%) were seizure-free for ⩾3 months at last follow up; of these, eight were seizure free for ⩾3 times the longest interictal interval before perampanel therapy; 18 (15%) had reduced seizure frequency ⩾50%. A total of 58 (47%) had an AE and 34 (28%) withdrew from treatment because of AEs. AEs included dizziness (33%), fatigue (12%), psychiatric symptoms (8%), cognitive deficits (7%), speech problems (5%), nausea (4%) and gait problems (4%). AEs subsided in 17/18 patients (94%) following a 2 mg dose reduction. A total of 43 (35%) took a concomitant enzyme inducer. Patients not taking enzyme inducers were more likely to be seizure free (p = 0.002); there were no other between-group differences. CONCLUSIONS:Perampanel was well tolerated and improved seizure control in 42% of patients (50- 100% reduction), with higher rates in those not receiving a concomitant enzyme inducer. AEs, particularly dizziness, were common but often disappeared with a slight dose reduction. The results are consistent with those from randomized controlled trials.

journal_name

Ther Adv Neurol Disord

authors

Rohracher A,Kalss G,Leitinger M,Granbichler C,Deak I,Dobesberger J,Kuchukhidze G,Thomschewski A,Höfler J,Trinka E

doi

10.1177/1756285616661115

subject

Has Abstract

pub_date

2016-11-01 00:00:00

pages

445-453

issue

6

eissn

1756-2856

issn

1756-2864

pii

10.1177_1756285616661115

journal_volume

9

pub_type

杂志文章
  • Implementation of computer-based language therapy in aphasia.

    abstract::A first step in evaluating the use of computers in language therapy for individuals with aphasia is to establish the treatment as active in small groups prior to large-scale clinical trials. The present study evaluated a comprehensive computer-based language therapy program in a group of eight individuals with chronic...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285609336548

    authors: Archibald LM,Orange JB,Jamieson DJ

    更新日期:2009-09-01 00:00:00

  • HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primary CNS lymphoma: a single center series.

    abstract:Background:To investigate outcome and toxicity of high-dose systemic methotrexate (HDMTX)-based polychemotherapy and intracerebroventricular (ICV) chemotherapy via an Ommaya reservoir in elderly patients with primary central nervous system lymphoma (PCNSL). Methods:We performed a retrospective analysis on patients ⩾65...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286420951087

    authors: Seidel S,Kowalski T,Margold M,Baraniskin A,Schroers R,Martus P,Schlegel U

    更新日期:2020-10-07 00:00:00

  • Neutralizing antibodies against interferon-Beta.

    abstract::The development of neutralizing antibodies (NAbs) is a major problem in multiple sclerosis (MS) patients treated with interferon-beta (IFN-ß). Whereas binding antibodies (BAbs) can be demonstrated in the vast majority of patients, only a smaller proportion of patients develop NAbs. The principle in NAb in vitro assays...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285608095144

    authors: Sorensen PS

    更新日期:2008-09-01 00:00:00

  • Treatment of neuromyelitis optica: current debate.

    abstract::Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that largely affects optic nerves and spinal cord. Recent studies have identified an elevation of serum anti-aquaporin 4 antibody as a hallmark of NMO. Typical cases of NMO significantly differ from multiple sclerosis (MS) in immunological markers, hi...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285608093978

    authors: Okamoto T,Ogawa M,Lin Y,Murata M,Miyake S,Yamamura T

    更新日期:2008-07-01 00:00:00

  • Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence.

    abstract::Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This review provides a summary of the cumulative dataset from clinical trials a...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285616628766

    authors: Khatri BO

    更新日期:2016-03-01 00:00:00

  • An update on the treatment of Sydenham's chorea: the evidence for established and evolving interventions.

    abstract::Over 320 years after Thomas Sydenham described the condition labelled Sydenham's chorea, it remains poorly understood. The disorder is an antineuronal antibody-mediated neuropsychiatric disorder caused by a poststreptococcal, autoimmune condition affecting control of movement, mood, behaviour and potentially the heart...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285610382063

    authors: Walker KG,Wilmshurst JM

    更新日期:2010-09-01 00:00:00

  • Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.

    abstract:OBJECTIVES:To assess clinical outcomes and patient satisfaction in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were switched from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG). METHODS:Eight consecutive patients, four...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285614563056

    authors: Hadden RD,Marreno F

    更新日期:2015-01-01 00:00:00

  • Longitudinal cortical network reorganization in early relapsing-remitting multiple sclerosis.

    abstract:Background:Network science provides powerful access to essential organizational principles of the brain. The aim of this study was to investigate longitudinal evolution of gray matter networks in early relapsing-remitting MS (RRMS) compared with healthy controls (HCs) and contrast network dynamics with conventional atr...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286419838673

    authors: Fleischer V,Koirala N,Droby A,Gracien RM,Deichmann R,Ziemann U,Meuth SG,Muthuraman M,Zipp F,Groppa S

    更新日期:2019-04-24 00:00:00

  • The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.

    abstract::B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and production of autoantibodies directed against myelin. Hence, the usage of B-cell-depleting monoclonal antibodies as therapy for autoimmune...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285615601933

    authors: Sorensen PS,Blinkenberg M

    更新日期:2016-01-01 00:00:00

  • The role of erenumab in the treatment of migraine.

    abstract::Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) have been the first class of specifically developed preventive treatments for migraine. Clinical trials data suggest superiority of the CGRP mAbs to placebo in terms of prevention of migraine symptoms, migraine-specific quality of life and headache re...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286420927119

    authors: Andreou AP,Fuccaro M,Lambru G

    更新日期:2020-05-27 00:00:00

  • Autoimmune glial fibrillary acidic protein astrocytopathy with lesions distributed predominantly in the entire spinal cord.

    abstract::Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy has been considered a novel central nervous system autoimmune disease characterized by relapse and responsiveness to corticosteroid with a specific GFAP-Immunoglobulin G (IgG) being noted in cerebrospinal fluid. We report the case of a 21-year-old girl p...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286420909973

    authors: Li XL,Han J,Zhao HT,Long YM,Zhang BW,Wang HY

    更新日期:2020-06-03 00:00:00

  • Botulinum toxin in the management of blepharospasm: current evidence and recent developments.

    abstract::Blepharospasm is a focal (although usually bilateral) dystonia of the orbicularis oculi muscles, producing excessive eye closure. This produces significant disability through functional blindness. Botulinum neurotoxins (BoNT) have become the treatment of choice for blepharospasm; the impressive response rate and the t...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285614557475

    authors: Hellman A,Torres-Russotto D

    更新日期:2015-03-01 00:00:00

  • Current and emerging therapies in multiple sclerosis: a systematic review.

    abstract::Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that preven...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285612450936

    authors: Castro-Borrero W,Graves D,Frohman TC,Flores AB,Hardeman P,Logan D,Orchard M,Greenberg B,Frohman EM

    更新日期:2012-07-01 00:00:00

  • Erythropoietin: still on the neuroprotection road.

    abstract::Acute stroke is one of the major causes of death and disabilities. Since the 1980s many clinical studies have been conducted to evaluate neuroprotective approaches to treat this important brain vascular event. However, to date the only drug approved (recombinant tissue plasminogen activator [rtPA]) represents a thromb...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285611434926

    authors: Subirós N,Del Barco DG,Coro-Antich RM

    更新日期:2012-05-01 00:00:00

  • Advances in imaging of brain abnormalities in neuromuscular disease.

    abstract::Brain atrophy, white matter abnormalities, and ventricular enlargement have been described in different neuromuscular diseases (NMDs). We aimed to provide a comprehensive overview of the substantial advancement of brain imaging in neuromuscular diseases by consulting the main libraries (Pubmed, Scopus and Google Schol...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286419845567

    authors: Angelini C,Pinzan E

    更新日期:2019-05-06 00:00:00

  • Current and future treatments for Alzheimer's disease.

    abstract::Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three choline...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285612461679

    authors: Yiannopoulou KG,Papageorgiou SG

    更新日期:2013-01-01 00:00:00

  • Application of immunotherapy for neurological manifestations in hypermobile Ehlers-Danlos syndrome.

    abstract::Ehlers-Danlos syndrome (EDS) is a heterogeneous heritable connective tissue disorder with various neurological manifestations, including chronic pain. The neurological manifestations in EDS are often regarded as being caused by the associated musculoskeletal disorders or polyneuropathy. Here, we present two patients w...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286418793766

    authors: Araki M,Lin Y,Ono H,Sato W,Yamamura T

    更新日期:2018-08-18 00:00:00

  • Natural toxins implicated in the development of Parkinson's disease.

    abstract::Experimental models of Parkinson's disease (PD) are of great importance for improving the design of future clinical trials. Various neurotoxic models are available, including 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat and rotenone. However, no model is considered perfect;...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285611413004

    authors: Salama M,Arias-Carrión O

    更新日期:2011-11-01 00:00:00

  • Efficacy and safety of laquinimod in multiple sclerosis: current status.

    abstract::Laquinimod is a novel immunomodulatory agent, in development as a potential disease-modifying treatment for multiple sclerosis (MS). Structurally related to linomide, its pharmacological predecessor, laquinimod combines anti-inflammatory and possibly clinically relevant neuroprotective effects with the convenience of ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285613499424

    authors: Haggiag S,Ruggieri S,Gasperini C

    更新日期:2013-11-01 00:00:00

  • Can inflammation be resolved in Alzheimer's disease?

    abstract::Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and dementia. Accumulating evidence suggests that inflammation is involved in the pathogenesis of AD. Epidemiological studies suggest that use of anti-inflammatory drugs is associated with a lower incidence of AD. However,...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286418791107

    authors: Zhu M,Wang X,Sun L,Schultzberg M,Hjorth E

    更新日期:2018-08-09 00:00:00

  • Diagnosis and management of essential tremor and dystonic tremor.

    abstract::Essential tremor (ET) is the most common adult movement disorder. Traditionally considered as a benign disease, it can cause an important physical and psychosocial disability. Drug treatment for ET remains poor and often unsatisfactory. Current therapeutic strategies for ET are reviewed according to the level of disco...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285609104791

    authors: Gironell A,Kulisevsky J

    更新日期:2009-07-01 00:00:00

  • C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis.

    abstract:Background:Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods:Levels of C3, C4, C5a, and ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286420935697

    authors: Aguirre F,Manin A,Fernandez VC,Justo ME,Leoni J,Paz ML,Villa AM

    更新日期:2020-08-10 00:00:00

  • Web-based interventions in multiple sclerosis: the potential of tele-rehabilitation.

    abstract::The World Wide Web is increasingly used in therapeutic settings. In this regard, internet-based interventions have proven effective in ameliorating several health behaviors, amongst them physical activity behavior. Internet-delivered interventions have shown positive effects on physical activity and physical function ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285616640684

    authors: Tallner A,Pfeifer K,Mäurer M

    更新日期:2016-07-01 00:00:00

  • Vascular medicine and thrombectomy in stroke.

    abstract::The treatment of stroke caused by intracranial vessel occlusion with intravenous recombinant tissue plasminogen activator (rt-PA) was the only evidence-based treatment option for a long time. Nevertheless the response rate was disappointing in large vessel occlusions. Five studies that evaluated the efficacy of mechan...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285617742082

    authors: Fischer S,Weber W

    更新日期:2017-11-22 00:00:00

  • Diagnosis and treatment of impulse control disorders in patients with movement disorders.

    abstract::Impulse control disorders are a psychiatric condition characterized by the failure to resist an impulsive act or behavior that may be harmful to self or others. In movement disorders, impulse control disorders are associated with dopaminergic treatment, notably dopamine agonists (DAs). Impulse control disorders have b...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285613476127

    authors: Mestre TA,Strafella AP,Thomsen T,Voon V,Miyasaki J

    更新日期:2013-05-01 00:00:00

  • New treatment option for partial-onset seizures: efficacy and safety of lacosamide.

    abstract::More than 30% of epilepsy patients remain refractory despite the advent of new antiepileptic drugs (AEDs) over two decades. Although a small percentage of these refractory patients may become seizure free when a new AED is added, combined administration of AEDs or the application of novel AEDs is the most common thera...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285609355850

    authors: Chung SS

    更新日期:2010-03-01 00:00:00

  • Wernicke-Korsakoff syndrome associated with mtDNA disease.

    abstract:Introduction:Wernicke encephalopathy (WE) and Wernicke-Korsakoff syndrome (WKS) are well-known disorders caused by thiamine deficiency. In addition to the classical concept of these diseases, some literature data suggest a connection between mitochondrial dysfunction and WE/WKS. Psychotic disorders and WKS seem to run ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286420938972

    authors: Jimoh IJ,Sebe B,Balicza P,Fedor M,Pataky I,Rudas G,Gal A,Inczedy-Farkas G,Nemeth G,Molnar MJ

    更新日期:2020-07-30 00:00:00

  • Choices for long-term hypertensive control in patients after first-ever hemorrhagic stroke: a nationwide cohort study.

    abstract:Background:To compare the long-term clinical outcomes of different antihypertensive drugs in stable patients after acute hemorrhagic stroke (HS). Methods:From January 2001 to December 2013, patients with first-ever primary HS were identified in the National Health Insurance Research Database, Taiwan. Patients with tra...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286418802688

    authors: Liu CH,Lin YS,Chi CC,Liou CW,Lee JD,Peng TI,Lee TH

    更新日期:2018-09-28 00:00:00

  • Paradoxical association of symptomatic cerebral edema with local hypoperfusion caused by the 'watershed shift' after revascularization surgery for adult moyamoya disease: a case report.

    abstract::Superficial temporal artery-middle cerebral artery anastomosis is generally considered as an effective method in improving damage associated with intracerebral occlusions in moyamoya disease. Hemodynamic changes caused by revascularization are the cause of many postoperative complications. Of the 186 consecutive surge...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286419878343

    authors: Yu J,Hu M,Yi L,Zhou K,Zhang J,Chen J

    更新日期:2019-09-25 00:00:00

  • Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis.

    abstract:Background:No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing-remitting multiple sclerosis (RRMS). Objective:To assess the NEDA status of...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286418795085

    authors: Arnold DL,Shang S,Dong Q,Meergans M,Naylor ML

    更新日期:2018-08-28 00:00:00